Hangzhou Haoyang Biotechnology Co., Ltd. se centra en proporcionar a los clientes anticuerpos, proteínas de fusión y productos tipo ADC, desde la evaluación temprana de la farmacocinética, el estudio farmacéutico IND hasta los servicios integrales de investigación y desarrollo y producción de producción comercial. Con sede en China, sirve a clientes globales.
'%3e%3cpath%20id='Vector'%20d='M11.3577%208.14503C11.447%208.23841%2011.5544%208.31273%2011.6732%208.3635C11.792%208.41428%2011.9199%208.44045%2012.0492%208.44045C12.1784%208.44045%2012.3063%208.41428%2012.4251%208.3635C12.544%208.31273%2012.6513%208.23841%2012.7407%208.14503L15.7036%205.19111C15.7972%205.10234%2015.8718%204.99543%2015.9228%204.87689C15.9738%204.75835%2016%204.63066%2016%204.50163C16%204.37259%2015.9738%204.24491%2015.9228%204.12637C15.8718%204.00783%2015.7972%203.90091%2015.7036%203.81215L12.7397%200.858226C12.6503%200.764845%2012.543%200.690527%2012.4241%200.639754C12.3053%200.588981%2012.1774%200.562805%2012.0482%200.562805C11.9189%200.562805%2011.791%200.588981%2011.6722%200.639754C11.5534%200.690527%2011.446%200.764845%2011.3567%200.858226L8.39478%203.81315C8.30112%203.90191%208.22654%204.00883%208.17556%204.12737C8.12459%204.24591%208.0983%204.37359%208.0983%204.50263C8.0983%204.63166%208.12459%204.75935%208.17556%204.87789C8.22654%204.99643%208.30112%205.10334%208.39478%205.19211L11.3577%208.14603V8.14503ZM6.41983%200.809227H0.987974C0.726546%200.809489%200.475858%200.913252%200.29072%201.09783C0.105582%201.2824%200.00105721%201.53278%200%201.7942L0%207.20906C0%207.75104%200.443988%208.19403%200.987974%208.19403H6.41983C6.68108%208.1935%206.93151%208.08962%207.11644%207.90508C7.30136%207.72053%207.40575%207.47031%207.4068%207.20906V1.7942C7.40575%201.53295%207.30136%201.28273%207.11644%201.09818C6.93151%200.913633%206.68108%200.809753%206.41983%200.809227ZM6.41983%207.20906H0.987974V1.7942H6.41983V7.20906ZM6.41983%209.179H0.987974C0.726719%209.17926%200.47618%209.28289%200.291071%209.46725C0.105961%209.65161%200.00132068%209.90172%200%2010.163L0%2015.5778C0%2016.1198%200.443988%2016.5628%200.987974%2016.5628H6.41983C6.68108%2016.5623%206.93151%2016.4584%207.11644%2016.2739C7.30136%2016.0893%207.40575%2015.8391%207.4068%2015.5778V10.163C7.40575%209.90172%207.30136%209.6515%207.11644%209.46696C6.93151%209.28241%206.68108%209.17853%206.41983%209.178V9.179ZM6.41983%2015.5788H0.987974V10.163H6.41983V15.5778V15.5788ZM14.8146%209.179H9.38275C9.12149%209.17926%208.87096%209.28289%208.68585%209.46725C8.50074%209.65161%208.3961%209.90172%208.39478%2010.163V15.5778C8.39478%2016.1198%208.83976%2016.5628%209.38275%2016.5628H14.8146C15.0759%2016.5623%2015.3263%2016.4584%2015.5112%2016.2739C15.6961%2016.0893%2015.8005%2015.8391%2015.8016%2015.5778V10.163C15.8005%209.90172%2015.6961%209.6515%2015.5112%209.46696C15.3263%209.28241%2015.0759%209.17853%2014.8146%209.178V9.179ZM14.8146%2015.5788H9.38275V10.163H14.8146V15.5778V15.5788Z'%20fill='white'/%3e%3c/g%3e%3cdefs%3e%3cclipPath%20id='clip0_132_1117'%3e%3crect%20width='16'%20height='16'%20fill='white'%20transform='translate(0%200.562805)'/%3e%3c/clipPath%3e%3c/defs%3e%3c/svg%3e)
Escenarios de aplicaciónLa empresa nacional inicia y la persona en el extranjero firma informes de prueba, cartas de autorización y otros documentos relacionados, pruebas genéticas de cooperación nacional y extranjera, negocios de investigación y desarrollo de medicamentos
'%3e%3cpath%20d='M5.4%2013.6128H10.5625C10.8375%2013.6128%2011.0875%2013.8253%2011.0875%2014.1378C11.0875%2014.4128%2010.875%2014.6628%2010.5625%2014.6628H5.4C5.125%2014.6628%204.875%2014.4503%204.875%2014.1378C4.875%2013.8253%205.0875%2013.6128%205.4%2013.6128ZM10.1375%2015.4378H5.825C5.75%2015.4378%205.725%2015.5378%205.7875%2015.6128L7.3625%2016.4253C7.5375%2016.5003%207.75%2016.5628%208%2016.5628C8.2125%2016.5628%208.3875%2016.4878%208.6%2016.4253L10.175%2015.6128C10.25%2015.5503%2010.2125%2015.4378%2010.1375%2015.4378ZM7.9%204.03781C8.5375%204.03781%209.0875%204.28781%209.65%204.81281C10.2125%205.30031%2010.4625%205.93781%2010.4625%206.71281C10.4625%206.96281%2010.675%207.23781%2010.9875%207.23781C11.2625%207.23781%2011.5125%206.98781%2011.5125%206.71281C11.5125%205.58781%2011.1625%204.71281%2010.425%204.05031C9.6875%203.38781%208.85%203.06281%207.9%203.06281C7.625%203.06281%207.375%203.27531%207.375%203.58781C7.4%203.78781%207.6125%204.03781%207.9%204.03781Z'%20fill='white'/%3e%3cpath%20d='M10.2747%2012.7378H5.68715C5.16215%2012.7378%204.73715%2012.3503%204.67465%2011.8253C4.59965%2011.7253%204.42465%2011.4753%204.36215%2011.4003C2.84965%2010.2378%201.97465%208.48781%201.97465%206.58781C1.96215%203.26281%204.66215%200.562805%207.99965%200.562805C11.3372%200.562805%2014.0372%203.2628%2014.0372%206.60031C14.0372%208.5253%2013.1622%2010.2878%2011.6122%2011.4378C11.5372%2011.5128%2011.3622%2011.7128%2011.2997%2011.8628C11.2247%2012.3128%2010.8122%2012.7378%2010.2747%2012.7378ZM5.82465%2011.5503H10.1372C10.2372%2011.1253%2010.6622%2010.6378%2010.8747%2010.4628C12.0997%209.5503%2012.7997%208.11281%2012.7997%206.56281C12.7997%203.90031%2010.6247%201.72531%207.96215%201.72531C5.29965%201.72531%203.12465%203.90031%203.12465%206.56281C3.12465%208.10031%203.82465%209.5128%205.04965%2010.4253C5.26215%2010.6003%205.71215%2011.0878%205.82465%2011.5503Z'%20fill='white'/%3e%3c/g%3e%3cdefs%3e%3cclipPath%20id='clip0_132_1239'%3e%3crect%20width='16'%20height='16'%20fill='white'%20transform='translate(0%200.562805)'/%3e%3c/clipPath%3e%3c/defs%3e%3c/svg%3e)
Soluciones'%20stroke-width='2'%20stroke-linecap='round'%20stroke-linejoin='round'/%3e%3cdefs%3e%3clinearGradient%20id='paint0_linear_132_1162'%20x1='2.16602'%20y1='11.8961'%20x2='13.666'%20y2='11.8961'%20gradientUnits='userSpaceOnUse'%3e%3cstop%20stop-color='%231063F1'/%3e%3cstop%20offset='1'%20stop-color='%231063F1'%20stop-opacity='0.5'/%3e%3c/linearGradient%3e%3c/defs%3e%3c/svg%3e)
La empresa nacional inicia la firma a través de eSignGlobal, y la persona de contacto de la parte cooperativa en el extranjero recibe el enlace del documento pendiente de firma a través del correo electrónico y entra en la firma a través de la autenticación de correo electrónico
La firma conjunta en el extranjero proporciona un canal de cooperación más fluido para la investigación y el desarrollo de medicamentos y los negocios de pruebas
